| Literature DB >> 33087084 |
Agnieszka M Frydrych1, Richard Parsons2, Omar Kujan3.
Abstract
BACKGROUND: Individuals seeking dental treatment often present with medical conditions which may affect dental treatment provision. The purpose of this study was to determine the prevalence of medical conditions and medication use among individuals attending dental clinics at a Western Australian tertiary institution.Entities:
Keywords: Cross-sectional; Dental institute; Dentistry; Systemic diseases; Western Australia
Mesh:
Year: 2020 PMID: 33087084 PMCID: PMC7579782 DOI: 10.1186/s12903-020-01285-2
Source DB: PubMed Journal: BMC Oral Health ISSN: 1472-6831 Impact factor: 2.757
General characteristics of the participants
| Variable | Total | Male | Female | |
|---|---|---|---|---|
| Age group (years) | 0.4519 | |||
| 25–34 | 105 | 40 (10.2) | 65 (13.6) | |
| 35–44 | 131 | 54 (13.7) | 77 (16.1) | |
| 45–54 | 137 | 61 (15.5) | 76 (15.9) | |
| 55–64 | 147 | 66 (16.8) | 81 (16.9) | |
| 65–74 | 228 | 112 (28.4) | 116 (24.2) | |
| 75–84 | 103 | 52 (13.2) | 51 (10.7) | |
| 85+ | 22 | 9 (2.3) | 13 (2.7) | |
| Tobacco use | < 0.0001 | |||
| Never | 481 | 168 (42.6) | 313 (65.5) | |
| Current | 201 | 109 (27.7) | 92 (19.3) | |
| Ex-user | 190 | 117 (29.7) | 73 (15.3) | |
| Tobacco (current/ex-user) | 0.5061* | |||
| Self-rolled | 19 | 10 (4.4) | 9 (5.5) | |
| Cigarette | 370 | 214 (94.7) | 156 (94.6) | |
| Chew/vape/other | 2 | 2 (0.9) | 0 (0.0) | |
| Alcohol use | 0.0002 | |||
| Never | 457 | 177 (44.9) | 280 (58.6) | |
| Current | 393 | 203 (51.5) | 190 (39.8) | |
| Ex-user | 22 | 14 (3.6) | 8 (1.7) | |
| Alcohol by type | 0.0001 | |||
| Spirits | 25 | 14 (9.3) | 11 (9.1) | |
| Wine | 133 | 56 (37.1) | 77 (63.6) | |
| Beer | 59 | 45 (29.8) | 14 (11.6) | |
| Cider | 6 | 3 (2.0) | 3 (2.5) | |
| Mixed | 49 | 33 (21.9) | 16 (13.2) | |
The p value compares each variable between male and female respondents
*Fisher’s Exact test
The prevalence of disease and medication usage among the cases
| Variable | Total | Males | Females | Odds ratio (Female relative to Male) (95% CI) | |
|---|---|---|---|---|---|
| Presence of disease | 753 (86.3) | 350 (88.8) | 403 (84.1) | 0.67 (0.45–0.99) | 0.0448 |
| Allergy | 282 (32.3) | 102 (25.9) | 180 (37.6) | 1.72 (1.29–2.31) | 0.0002 |
| Auditory system disorder | 11 (1.3) | 5 (1.3) | 6 (1.3) | 0.99 (0.30–3.26) | 1.0* |
| Blood disorder | 23 (2.6) | 6 (1.5) | 17 (3.6) | 2.38 (0.93–6.09) | 0.0629 |
| Cancer | 100 (11.5) | 48 (12.2) | 52 (10.9) | 0.88 (0.58–1.33) | 0.5402 |
| Cardiovascular disease | 331 (37.9) | 153 (38.8) | 178 (37.2) | 0.93 (0.71–1.23) | 0.6124 |
| Gastrointestinal system disorder | 118 (13.5) | 51 (12.9) | 67 (14.0) | 1.09 (0.74–1.62) | 0.6537 |
| Endocrine system disorder | 196 (22.4) | 81 (20.6) | 115 (24.0) | 1.22 (0.88–1.68) | 0.2241 |
| Diabetes | 136 (15.6) | 63 (16.0) | 73 (15.2) | 0.94 (0.65–1.36) | 0.7611 |
| Dyslipidaemia | 38 (4.4) | 15 (3.8) | 23 (4.8) | 1.27 (0.66–2.48) | 0.4736 |
| Other endocrine | 49(5.6) | 10 (2.5) | 39 (8.1) | 3.40 (1.68–6.91) | 0.0003 |
| Immune system disorder | 38 (4.4) | 19 (4.8) | 19 (4.0) | 0.82 (0.43–1.56) | 0.5377 |
| Zoonotic diseases | 15 (1.7) | 13 (3.3) | 2 (0.4) | 0.12 (0.03–0.55) | 0.0011 |
| Liver disease | 15 (1.7) | 7 (1.8) | 8 (1.7) | 0.94 (0.34–2.61) | 0.9041 |
| Mental health disorder | 257 (29.4) | 102 (25.9) | 155 (32.4) | 1.37 (1.02–1.84) | 0.0368 |
| Musculoskeletal system disorder | 201 (23.0) | 92 (23.4) | 109 (22.8) | 0.97 (0.70–1.33) | 0.8355 |
| Nervous system | 108 (12.4) | 51 (12.9) | 57 (11.9) | 0.91 (0.61–1.36) | 0.6409 |
| Renal system | 29 (3.3) | 13 (3.3) | 16 (3.3) | 1.01 (0.48–2.13) | 0.9733 |
| Reproductive system | 35 (4.0) | 9 (2.3) | 26 (5.4) | 2.46 (1.14–5.30) | 0.0185 |
| Respiratory system disorder | 155 (17.8) | 68 (17.3) | 87 (18.2) | 1.06 (0.75–1.51) | 0.7280 |
| Asthma | 5 (10.9) | 39 (9.9) | 56 (11.7) | 1.21 (0.78–1.86) | 0.3974 |
| COPD | 32 (3.4) | 18 (4.6) | 14 (2.9) | 0.63 (0.31–1.28) | 0.1978 |
| Other | 41 (4.7) | 17 (4.3) | 24 (5.0) | 1.17 (0.62–2.21) | 0.6287 |
| Skin conditions | 26 (3.0) | 14 (3.6) | 12 (2.5) | 0.70 (0.32–1.53) | 0.3646 |
| Viral infections | 48 (5.5) | 26 (6.6) | 22 (4.6) | 0.68 (0.38–1.22) | 0.1957 |
| Visual system disorder | 35 (4.0) | 16 (4.1) | 19 (4.0) | 0.98 (0.50–1.92) | 0.9436 |
| Other disease | 5 (0.6) | 1 (0.3) | 4 (0.8) | 3.31 (0.37–29.73) | 0.3854* |
| Taking Medication | 699 (80.0%) | 317 (80.5) | 382 (79.9) | 0.97 (0.69–1.35) | 0.8421 |
| Ace inhibitor | 86 (9.9%) | 51 (12.9) | 35 (7.31) | 0.53 (0.34–0.83) | 0.0054 |
| Alpha Blockers | 5 (0.6) | 4 (1.0) | 1 (0.2) | 0.20 (0.02–1.83) | 0.1811* |
| Analgesics | 150 (17.2) | 59 (15.0) | 91 (19.0) | 1.33 (0.93–1.91) | 0.1168 |
| Opioid | 69 (7.9) | 36 (9.1) | 33 (6.9) | 0.74 (0.45–1.20) | 0.2206 |
| Non-opioid | 106 (12.1) | 34 (8.6) | 72 (15.0) | 1.87 (1.22–2.88) | 0.0040 |
| Antiarrhythmic | 7 (0.8) | 2 (0.5) | 5 (1.0) | 2.07 (0.40–10.71) | 0.4668* |
| Anticoagulants | 150 (17.2) | 84 (21.3) | 66 (13.8) | 0.59 (0.41–0.84) | 0.0033 |
| Anticonvulsants and antiepileptics | 73 (8.4) | 27 (6.9) | 46 (9.6) | 1.44 (0.88–2.37) | 0.1440 |
| Antidepressants | 197 (22.6) | 65 (16.5) | 132 (27.6) | 1.93 (1.38–2.69) | 0.0001 |
| SNRI | 39 (4.5) | 15 (3.8) | 24 (5.0) | 1.33 (0.69–2.58) | 0.3918 |
| SSRI | 79 (9.0) | 23 (5.8) | 56 (11.7) | 2.14 (1.29–3.54) | 0.0027 |
| Tricyclic | 25 (2.9) | 7 (1.8) | 18 (3.8) | 2.16 (0.89–5.22) | 0.0807 |
| Combination | 22 (2.5) | 10 (2.5) | 12 (2.5) | 0.99 (0.42–2.31) | 0.9754 |
| Other | 32 (3.7) | 10 (2.5) | 22 (4.6) | 1.85 (0.86–3.95) | 0.1079 |
| Antihistamine | 19 (2.2) | 9 (2.3) | 10 (2.1) | 0.91 (0.37–2.27) | 0.8466 |
| Antihypertensive NOS | 38 (4.3) | 24 (6.1) | 14 (2.9) | 0.46 (0.24–0.91) | 0.0224 |
| Anti-inflammatories | 74 (8.5) | 25 (6.4) | 49 (10.2) | 1.68 (1.02–2.78) | 0.0403 |
| Corticosteroid | 26 (3.0) | 10 (2.5) | 16 (3.3) | 1.33 (0.60–2.96) | 0.4878 |
| NSAID | 51 (5.8) | 16 (4.1) | 35 (7.3) | 1.86 (1.01–3.42) | 0.0419 |
| Antiemetics | 11 (1.3) | 2 (0.5) | 9 (1.9) | 3.76 (0.81–17.5) | 0.1238* |
| Antimicrobial | 35 (4.0) | 15 (3.8) | 20 (4.2) | 1.10 (0.56–2.18) | 0.7825 |
| Antipsychotic | 60 (6.9) | 27 (6.9) | 33 (6.9) | 1.01 (0.59–1.70) | 0.9830 |
| Beta blockers | 91 (10.4) | 45 (11.4) | 46 (9.6) | 0.82 (0.53–1.27) | 0.3817 |
| Bisphosphonates | 9 (1.0) | 3 (0.8) | 6 (1.3) | 1.65 (0.41–6.65) | 0.5242* |
| Calcium channel blockers | 55 (6.3) | 31 (7.9) | 24 (5.0) | 0.62 (0.36–1.07) | 0.0838 |
| Chemotherapeutics | 7 (0.8) | 4 (1.0) | 3 (0.6) | 0.61 (0.14–2.76) | 0.7072* |
| Diuretics | 34 (3.89) | 18 (4.6) | 16 (3.3) | 0.72 (0.36–1.43) | 0.3506 |
| Anxiety and sleep disorders | 66 (7.6) | 30 (7.6) | 36 (7.5) | 0.99 (0.60–1.63) | 0.9563 |
| Drugs for Diabetes | 105 (12.0) | 55 (14.0) | 50 (10.4) | 0.72 (0.48–1.08) | 0.1115 |
| Drugs for dyslipidaemia | 181 (20.7) | 98 (24.9) | 83 (17.3) | 0.63 (0.46–0.88) | 0.0062 |
| Statin | 156 (17.9) | 85 (21.6) | 71 (14.8) | 0.63 (0.45–0.90) | 0.0096 |
| Fibrate | 15 (1.7) | 8 (2.0) | 7 (1.5) | 0.72 (0.26–1.99) | 0.5197 |
| Other | 18 (2.1) | 8 (2.0) | 10 (2.1) | 1.03 (0.40–2.63) | 0.9528 |
| Gastrointestinal NOS | 9 (1.0) | 5 (1.3) | 4 (0.8) | 0.66 (0.17–2.46) | 0.5276 |
| Genitourinary | 23 (2.6) | 18 (4.6) | 5 (1.0) | 0.22 (0.08–0.60) | 0.0012 |
| H2 antagonists | 9 (1.0) | 4 (1.0) | 5 (1.0) | 1.03 (0.27–3.86) | 1.0* |
| Hormones | 111 (12.7) | 23 (5.8) | 88 (18.4) | 3.63 (2.25–5.87) | < 0.0001 |
| Immunosupressants | 36 (4.1) | 17 (4.3) | 19 (4.0) | 0.92 (0.47–1.79) | 0.7969 |
| Inhaled | 106 (12.1) | 42 (10.7) | 64 (13.4) | 1.29 (0.85–1.96) | 0.2240 |
| Laxatives | 10 (1.1) | 6 (1.5) | 4 (0.8) | 0.54 (0.15–1.94) | 0.3600* |
| Muscle relaxants | 5 (0.6) | 3 (0.8) | 2 (0.4) | 0.55 (0.09–3.29) | 0.6626* |
| Nitrates and anti-anginal | 18 (2.1) | 9 (2.3) | 9 (1.9) | 0.82 (0.32–2.08) | 0.6749 |
| Other drugs affecting bone | 21 (2.4) | 4 (1.0) | 17 (3.6) | 3.59 (1.20–10.75) | 0.0150 |
*Fisher’s Exact test
The effect of age group, gender, smoking and alcohol use on positive medical history and medication use
| Variable | Male | Female | |
|---|---|---|---|
| Medical history | |||
| Age group (years) | |||
| 25–34 | 34/40 (85.0) | 39/65 (60.0) | 0.0069 |
| 35–44 | 41/54 (75.9) | 60/77 (77.9) | 0.7890 |
| 45–54 | 51/61 (83.6) | 63/76 (82.9) | 0.9118 |
| 55–64 | 60/66 (90.9) | 70/81 (86.4) | 0.3972 |
| 65–74 | 106/112 (94.6) | 108/116 (93.1) | 0.6284 |
| 75–84 | 50/52 (96.2) | 51/51 (100.0) | 0.4951* |
| 85+ | 8/9 (88.9) | 12/13 (92.3) | 1.0* |
| Medication | |||
| Age group (years) | |||
| 25–34 | 27/40 (67.5) | 36/65 (55.4) | 0.2185 |
| 35–44 | 35/54 (64.8) | 52/77 (67.5) | 0.7458 |
| 45–54 | 43/61 (70.5) | 58/76 (76.3) | 0.4415 |
| 55–64 | 53/66 (80.3) | 68/81 (84.0) | 0.5643 |
| 65–74 | 101/112 (90.2) | 107/115 (93.0) | 0.4358 |
| 75–84 | 50/52 (96.2) | 50/51 (98.0) | 1.0* |
| 85+ | 8/9 (88.9) | 11/13 (84.6) | 1.0* |
| Medical history | |||
| Tobacco use | |||
| Never | 147/168 (87.5) | 259/313 (82.8) | 0.1708 |
| Current | 99/109 (90.8) | 74/92 (80.4) | 0.0340 |
| Ex-user | 104/117 (88.9) | 69/73 (94.5) | 0.1859 |
| Medication | |||
| Tobacco use | |||
| Never | 130/168 (77.4) | 244/313 (78.2) | 0.8355 |
| Current | 87/109 (79.8) | 75/92 (81.5) | 0.7607 |
| Ex-user | 100/117 (85.5) | 62/73 (84.9) | 0.9189 |
| Medical history | |||
| Alcohol use | |||
| Never | 158/177 (89.3) | 230/280 (82.1) | 0.0383 |
| Current | 181/203 (89.2) | 164/190 (86.3) | 0.3891 |
| Ex-user | 11/14 (78.6) | 8/8 (100.0) | 0.2727* |
| Medication | |||
| Alcohol use | |||
| Never | 145/177 (81.9) | 222 (79.6) | 0.5370 |
| Current | 161/203 (79.3) | 151/190 (79.5) | 0.9681 |
| Ex-user | 11/14 (78.6) | 8/8 (100.0) | 0.2727* |
*Fisher’s Exact test
The effect of IRSADa (mean, standard deviation, number) on positive medical history and medication use
| Variable | Male (N = 394) | Female (N = 479) | |
|---|---|---|---|
| Medical history | |||
| No | 1035 [60.1], 44 | 1025 [64.7], 76 | 0.4117 |
| Yes | 1038 [64.3], 350 | 1031 [67.3], 403 | 0.1335 |
| Medication | |||
| No | 1029 [63.7], 77 | 1034 [67.6], 96 | 0.6230 |
| Yes | 1040 [63.7], 317 | 1029 [66.8], 382 | 0.0298 |
aIRSAD—The Index of Relative Socio-Economic Advantage and Disadvantage (Australian Bureau of Statistics)